We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Care for patients with rheumatic diseases during COVID‐19 pandemic: A position statement from APLAR.
- Authors
Tam, Lai‐Shan; Tanaka, Yoshiya; Handa, Rohini; Chang, Chi‐Chen; Cheng, Yew Kuang; Isalm, Nazrul; Li, Mengtao; Lorenzo, Jose Paulo; Song, Yeong‐Wook; Yamamoto, Kazuhiko; Zeng, Xiaofeng; Haq, Syed Atiqul
- Abstract
Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in China in December 2019. Health authorities should ensure adequate supply of these drugs since the HCQ shortage not only will limit availability to patients with COVID-19 if efficacy is truly established but also represents a real risk to patients with rheumatic diseases. On the other hand, rheumatologists are cautiously enthusiastic that a variety of immune-modulating drugs and targeted cytokine inhibitors available for rheumatic disease patients may also benefit patients as prophylaxis for COVID-19 or with COVID-19-induced CSS.
- Subjects
COVID-19 pandemic; RHEUMATISM; INTERSTITIAL lung diseases; COMMUNITY-acquired pneumonia; PHYSICIANS; COVID-19; MEDICAL personnel
- Publication
International Journal of Rheumatic Diseases, 2020, Vol 23, Issue 6, p717
- ISSN
1756-1841
- Publication type
Article
- DOI
10.1111/1756-185X.13863